HYDRALLAZINE-INDUCED SJOGRENS SYNDROME
HYDRALLAZINE-INDUCED SJOGRENS SYNDROME
复制标题
DOI：
10.1016/s0901-5027(88)80157-7
复制
发表时间：
1988-04-01
影响因子：
2.4
通讯作者：
CONNELL, JMC
中科院分区：
文献类型：
--
作者：
DARWAZA, A;LAMEY, PJ;CONNELL, JMC
一名60岁男性患者开始使用盐酸肼屈嗪（治疗高血压）治疗4年后，出现干燥综合征的临床特征，并具有药物性系统性红斑狼疮的免疫学特征。此外，患者描述了类似类风湿性关节炎的症状，泪腺和腮腺唾液流量减少，但唇腺活检缺乏干燥综合征的典型特征。停止肼屈嗪治疗1年后，临床参数恢复正常。
4 years after initiation of therapy with hydralazine hydrochloride (for treatment of hypertension), a 60-year-old male patient developed clinical features of Sjogren''s syndrome, with immunological features of drug-induced systemic lupus erythematosus. In addition, the patient described rheumatoid arthritis-like symptoms and had reduced lacrimal and parotid salivary flow, but lacked the typical features of Sjogren''s syndrome on labial gland biopsy. 1 year after discontinuation of hydralazine therapy, the clinical parameters returned to normal.